

April 1, 2015

Susan Buchbinder & Hyman Scott Bridge HIV, San Francisco Department of Public Health



POPULATION HEALTH DIVISION SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH



Disclosures

I have no financial disclosures.

The views expressed herein do not necessarily reflect the official policies of the City and County of San Francisco; nor does mention of the San Francisco Department of Public Health imply its endorsement.






Outline

- S Pre-Exposure Prophylaxis
 - PROUD
 - Ipergay
 - Partners PrEP + TasP
 - FACTS 001
 - Safety
- s HIV Epidemiology
- s Hormonal Contraception
- s A few other interesting abstracts





Pragmatic Open-Label Randomized Trial of Pre-Exposure Prophylaxis: PROUD Study



Primary endpoint: Secondary endpoints: HIV seroconversion between randomization and Month 12 Safety, adherence, sexual behavior, resistance development

Oct 16, 2014: the PROUD Trial Steering Committee announced that participants on the deferred arm of the study, who had not yet started PrEP, would be offered the opportunity to begin PrEP ahead of schedule



CAI: Condomless anal intercourse

All subjects received comprehensive HIV prevention services, including condoms, risk-reduction counseling, testing and treatment for sexually transmitted infections, and HIV pre- and post-test counseling



Demographics and PrEP Use

	Immediate	Deferred
Age, median (IQR)	35 (30-43)	35 (29-42)
White Race	80%	82%
Born UK (No)	40%	40%
Education (University)	59%	60%
Full Time Employment	70%	73%
Currently Single	53%	55%
Recreational drug use	76%	64%


- 14 (5%) of those in the immediate arm never started PrEP.
- Overall, drug prescribed covered 86% of days of follow-up.
 - Rare use of PrEP in the deferred arm
 - •PEP use common 83 (31%) of participants



Individual Incident HIV Infections

Immediate N=3

Delayed N=19



PROUD Results

HIV Incidence

			Incidence/100 person-years
Group	Infections, n	Follow-up (PY)	(90% CI)
Overall	22	453	4.9 (3.4-6.8)
Immediate	3	239	1.3 (0.4-3.0)
Deferred	19	214	8.9 (6.0-12.7)


86% (90% CI 58-96%) Risk Reduction *P*=0.0002 Number needed to treat=13 (90% CI: 9-25)

Resistance: 3 individuals developed M184V/I, no K65R




CPN BUILDING THE CAPACITY OF THE NATION'S HIV PREVENTION WORKFORCE

Reported Sexual Risk Behavior and STIs




974 Screens in Immediate Group 749 Screens in the Delayed Group

Ipergay Trial




Funded by Centers for Disea

Ipergay Event Level PrEP



POPULATION NEALTH DIVISION IAN FRANCISCO DEPARTMENT OF PUPUL HEALTH

Months



0.02 0.00 Placebo, n FTC/TDF, n

> 86% relative reduction (95% CI: 40-99, *P*=0.002) 16 subjects infected

Placebo=14 Incidence 6.6; FTC/TDF=2 Incidence 0.94 Number needed to treat: 18

POPULATION NEALTH DIVISION AN PLANCISCO DEPARTMENT OF PURILE HEALTH

Funded by Centers for Disease Control and Prevention

Safety

- s PrEP interrupted by 28 participants (from both groups)
- Only 13 thought to be related to Truvada:
 - Nausea, diarrhea, abd pain, or fatigue (n-5)
 - Decline in CrCl (n=2)
 - Headache (n=2)
 - Joint pain (w fatigue in one case) (n=2)
 - Sleep disturbance (n=1)
 - Flu-like illness (n=1)

PrEP was restarted in 11/13 participants.





Adherence to PrEP Surrounding Recent Sexual Intercourse – CASI Assessment

PrEP use, % (min-max)	FTC/TDF n=649 sex events	Placebo n=563 sex events	Total % (min-max)
Correct use*	45 (36-57)	40 (22-49)	43 (35-51)
Suboptimal use	27 (14-35)	31 (18-44)	29 (20-38)
No PrEP	27 (15-37)	29 (24-44)	28 (20-38)

*According to the protocol or at least one pill before and one pill after sex



Median Number of pills used per month 16 (10-23) in placebo arm 16 (12-24) in FTC/TDF arm



Sexually Transmitted Infections

	FTC/TDF n=199 N (%)	Placebo n=201 N (%)	P-value
Chlamydia	43 (22)	34 (17)	0.23
Gonorrhea	38(19)	45 (22)	0.42
Syphilis	19 (10)	19 (10)	0.98
HCV	3 (<2)	3 (<2)	1.0
Any STI	76 (38)	65 (32)	0.22

70% reported condomless anal sex throughout the study





Adverse Events

	FTC/TDF, n=199 N (%)	Placebo, n=201 N (%)	P-value
Any AE	184 (92)	178 (89)	0.18
Any Serious AE	18 (9)	16 (8)	0.70
Any Grade 3 or 4 AE	17 (9)	14 (7)	0.56
Tx D/C 2° to AE	1	0	
Drug Related GI AEs	25 (13)	11 (6)	0.013
Nausea/vomiting	15	2	
Abd pain	11	4	
Diarrhea	7	5	
Grade 1 Creatinine	28 (14)	15 (7)	0.042
Proteinuria <u>></u> 2+	10 (5)	9 (5)	0.83
Glycosuria <u>></u> 2+	1 (1)	0 (0)	1.00
All Grade ALT	33 (17%)	26 (13%)	0.37
Grade 3 or 4 ALT	1 (1)*	4 (4)**	0.36



* Acute HCV infection

** Acute HCV in 3 and syphilis in one



CDC Press Statement

For Immediate Release:Tuesday, February 24, 2015 Contact: <u>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention</u> (404) 639-8895 <u>NCHHSTPMediaTeam@cdc.gov</u>

CDC Statement on IPERGAY Trial of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention among Men Who Have Sex with Men

"...CDC continues to recommend daily dosing of PrEP and urges people at substantial risk for HIV infection and their health care providers to continue to follow current CDC guidelines."






Baeten. #29 Mujugira #98<mark>9</mark>

Partners PrEP + TasP for HIV Serodiscordant Couples

PrEP is offered as a 'bridge' for the first 6 months after ART initiation by the HIV-infected partner




Baeten #29 Mujugira #989 Partners PrEP + TasP: HIV Incidence N=39.7 infections 6 Incidence rate=5.2 (95% CI: 3.7-6.9) 5 IRR observed vs. expected = Limited PrFP use in the 2 8 0.04 (95% CI: 0.01-0.19) HIV seroconverters. **HIV incidence rate** or a 4 96% reduction Both: Started PrFP but 3 reported breaks in use. Undetectable plasma 2 tenofovir concentrations at the time of N=2 infections seroconversion. Incidence rate=0.2 (95% CI: 0.0-0.9) 0 **Expected** Observed **Incidence Model** Incidence The observed HIV incidence is a 96% (95% CI 81-99%) P<0.0001 reduction com to the expected incidence rate

CO DEPARTMENT OF PUBLIC HEA

FACTS 001

Phase III RCT 18-30 years, HIV negative, sexually active women Not pregnant, Willing to use effective contraception and condoms No renal, hepatic, pelvic or bone disease Enrolled irrespective of HSV-2, Hepatitis B or breastfeeding status



Baseline Characteristics

	TFV gel n= 1015 %	Placebo gel N=1014 %
Mean Age (IQR)	23 (20-25)	23 (20-25)
Single	89%	89%
Living with parents/siblings	61%	63%
Secondary Educ. Or higher	56%	56%
Anal sex	1%	1%
Consistent condom use	35%	32%
Perceived HIV risk > than usual	18%	17%
Median no. of partners	1 (1-1)	1 (1-1)
HSV-2 seroprevalence	43%	40%

POPULATION NEALTH DIVISION SAN PRANCISCO DEPARTMENT OF PURLIC HEALTH



ATION'S HIV

Primary Effectiveness Results (mITT)

	TFV gel N= 1015 %	Placebo gel N=1014 %
Person Years	1515	1521
HIV Infections	61	62
HIV Incidence per 100 py (95% CI)	4.0 (3.1-5.2)	4.0 (3.1-5.2)

Incident Rate Ratio 1.0 (95% CI 0.7-1.4)





Adherence

- Case-cohort of 214 women with 1075 cervical vaginal lavage (CVL) samples
 64% of samples with any TFV detected
- Servent of women:
 - 22% TFV detected at all quarterly visits
 - 65% TFV detected at some quarterly visits
 - 13% TFV never detected at quarterly visits


TFV detected in samples from women who reported sex in 10 days preceding CVL



aHR 0.48 (0.23-97) p=0.04



Variable PrEP Engagement in iPrEx OLE



PrEP Adverse Events And Resistance

P	
Adverse Event	
Start-up Syndrome	1-18.5% with nausea, vomiting +/- dizziness
Renal Toxicity	0.2% Grade 2-4 Creatinine elevations among 5469 ppts randomized to TDF/FTC
Bone Mineral Density	0.4-1.5% BMD loss. Return toward baseline after d/c. No increased fracture risk.
HIV Resistance among seroconverters	3.7% (9/243) 0.06% of those receiving PrEP after excluding likely transmitted resistance





Estimated SF PrEP eligibles and users

Group	People
HIV negative at substantial risk: MSM with 2+ ncAI partners ¹ MSM with 0 ncAI and an STI in the last year ² Female partners of HIV+ MSM ³ Trans women ⁴	12,589 2,325 653 522
TOTAL estimated PrEP eligibility	16,089
TOTAL reporting PrEP in past year	5,059
Percent of eligible people using PrEP in past year	31%

- 1. SF City Clinic 2014 survey x HIV negative MSM population of 50,000;
- 2. SF NHBS self report of STI among MSM with 0 ncAI in 2014 x HIV negative MSM population of 50,000;
- 3. SF NHBS MSM reporting female partners in 2014 x HIV positive MSM population of 14638.
- 4. IDU and ncRAI in est. 923 HIV negative trans women in SF adapted from Wilson BMCID 2014 14:430.
- 5. SF NHBS 2014, data on file.



Grant CROI Abstract 25 Seattle 2015.



New PrEP Agents

- Maraviroc HPTN 069/ACTG A5305
- S Long Acting Agents
 - Rilpivirine LA HPTN 076
 - Cabotegravir HPTN 077/ÉCLAIR
 - Immunotherapies (VRC01) HVTN / HPTN 081






Maraviroc

- Maraviroc does concentrate in rectal tissue compared to plasma.
- However, single dose of 600mg or 300mg did not prevent ex vivo R5 HIV-1 infection in rectal mucosa 4 hours after dosing.
- Complete inhibition of infection in those receiving Truvada for 10 days.
- PK/PD study also showed lack of efficacy in vaginal and rectal ex vivo HIV-1 challenge.
 - Fox Abstract #86LB





Funded by Centers for Disease Control and Prevention

Themed Discussion


- Recent meta analysis of 18 studies (37, 124 women).
 - aHR compared to no HC:
 - **s** DMPA 1.50 (1.25-1.83)
 - **s** NET-EN 1.24 (0.84-1.82)
 - s COC 1.03 (0.88-1.20)
 - Effect estimates reduced for studies at lower risk of bias DMPA 1.22 (0.99-1.5)
- Several mechanisms for biological plausibility including CCR5.





Morrison et al PLoS Medicine, 2015

Hormonal Contraception



- 1. Thinning of the epithelium
- 2. Disruption of tight junctions
- 3. Upregulation of syndecans
- 4/5. Increases in pro-inflammatory or decrease in protective mediators
- 6. Increases in CCR5 expressions
- 7/8. Changes in microbiome
- 9. Increase in HSV or other STIs, ulcerative lesions





Changes in CCR5 Expression and Vaginal Microbiome

- s Estrogen replacement was associated with <u>lower</u> CCR5+ Expression in postmenopausal women.
 - Meditz Abstract # 859
- s CCR5+ expression in CD4+ and CD8+ T cells from the peripheral blood was <u>higher</u> among women using the levonorgestrel releasing-IUD.
 - Tsibiris Abstract #858
- Rise in progesterone during luteal phase associated with <u>increased</u> CCR5+ expression.
 - Swaims Abstract #862
- S DMPA led to sustained, and statistically significant <u>declines</u> in vaginal bacterial concentration and cytokine levels.
 - Roxy Abstract #861





Treatment as Prevention & & Epidemiology



SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH



Funded by Centers for Disease Control and Prevention

Time with HIV VL >1500 copies/ml

- Solution Sol
- **s** 4/1/2009- 3/31/2013, followed for at least 12 months.
 - 90.5% prescribed ART
- Multiple viral loads provides a longitudinal view of VL results.
 - Median #Viral load test: 9 (2-40)





Time with HIVVL >1500 copies/ml

23.1% of observed time VL exceeded 1,500 copies 54% of patients had some time above 1,500 copies

N=14,532	% of time VL exceeded 1500 copies	Adjusted rate ratio	95% CI	p-value
Age at initial VL in analysis 16-39	32.1	1.38	1.30, 1.46	<0.001
40-49	22.8	1.18	1.12, 1.25	<0.001
50-85	16.5	ref.		
Race/ethnicity Black	26.1	1.24	1.16, 1.32	<0.001
Hispanic	19.7	0.98	0.90, 1.06	0.610
Other	12.4	0.72	0.55, 0.93	0.011
White	16.0	ref.		
Gender/orientation MSM	20.1	0.94	0.89, 0.99	0.024
Women	25.1	1.01	0.97, 1.06	0.588
Heterosexual Men	23.6	ref.		


Higher % time above 1500 copies:


- 1. Young pts
- 2. Black pts
- 3. Pts not on ART
- 4. Pts with more intervals
 >6 months between VL measures
- 5. Medicaid or Ryan White.


No adherence data or sexual risk behavior data

Increasing racial/ethnic HIV disparities among US MSM

- Used nationally representative CDC Data from 20 US cities – NHBS.
- Black MSM had higher HIV prevalence, and had lower awareness of HIV infection.










Declines in "Late" Diagnoses

- s 24% of HIV diagnoses were "late" in 2012
- Percentage of late diagnoses decreased overall, but few areas were <20%.
- Racial/ethnic disparities
 in late diagnoses:
 Blacks 38/105 MSAs;
 Latinos 68/105 MSAs






CPN BULDING THE CAPACITY OF THE NATION'S HIV PREVENTION WORK/FORCE Funded by Centers for Disease Central and Prevention


Increased Awareness of HIV Infection

- S De-identified serosurveys conducted on 18,240 untargeted adult JHH-ED patients between 1987-2013.
- Trends in HIV prevalence, cross-sectional incidence estimates, viral load and HCV prevalence.
- S JHH ED HIV testing and linkage to care programs were initiated in 2005 and continue to date.





Viral Suppression and HIV Incidence



Financial Incentives



POPULATION HEALTH DIVISION SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH



Funded by Centers for Disease Control and Prevention


HPTN 065

 Goal to determine feasibility of financial incentives to linkage to care and viral suppression

s 38 Sites– NYC & DC


[Most patients in care at these Sites]






Linkage to Care

Change in Linkage to Care, by Test Site



Viral Suppression

Change in Proportion with VS, by Site



Other Interesting Abstracts



SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH



Funded by Centers for Disease Control and Prevention


Stigma

- 76% of 4,385 participants in MMP endorsed at least one HIV-related stigma questions.
 - Stigma scores were associated with depression, nondisclosure of HIV status to all sex partners, nonadherence to ART, and lack of viral suppression.
 - Baugher Abstract #1057
- 89% of women and 81% of men in 18 countries in SSA reported HIV-related stigma.
 - For each 10% increase in ART coverage, there was a 2% (significant) decline in reported HIV-related stigma.
 - Chan Abstract #1059





Global Engagement in HIV Continuum Among MSM



PRIORITY

PLAT BATE OVER OPE

TRACKED INSURE:


HOME HIV Testing

- Used Grindr to advertise free home HIV self-test kits.
- Sover 6 weeks received 12,000 visits to their website and 334 test requests.
 - 28% had tested >12 months prior
 - 11% had never been tested
 - Two new HIV+ Both linked to care.






Figure 2: Number of HIV self-test kit requests by delivery method




Serosorting

s Retrospective cohort of 186 MSM newly diagnosed with HIV



Serosorting

Stable serosorting among HIV negative MSM over the same time period.



Thank you

- s Hyman Scott
 s Brad Hare
- s Albert Liu
- s Harry Lampiris
- s Cait Koss
- s Carina Marquez

Boston Mark Your 2016 Calendar!



CROI 2016 will be held at the Hynes Convention Center in Boston, Massachusetts, from February 22 to 25, 2016.

